InsiderSource
BBIO

BridgeBio Pharma, Inc.

SEC CIK 1743881
$66.80 −11.2% · 90 days
90-day buys
$0
0 open-market
90-day sells
$19.38M
41 open-market
Net insider flow
−$19.38M
Net selling
Filings shown
109
Most recent
Advertisement

At a glance

Over the last 90 days, insiders at BBIO have sold a net $19.38M of stock (0 open-market buys vs 41 sells).

Largest recent trade: Ellis Andrea sold $4.21M of BBIO, trimming their stake 78%.

Most active filer: Kumar Neil, with 80 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for BBIO, newest first
View on SEC EDGAR ↗
BBIO
BridgeBio Pharma, Inc.
Sell Ellis Andrea · Director · Open-market sale · filed Mar 6, 2026 ΔOwn −78%

Ellis Andrea sold $4.21M of BBIO, trimming their stake 78%.

−$4.21M
64,921 sh @ $65
BBIO
BridgeBio Pharma, Inc.
Sell Valantine Hannah · Director · Open-market sale · filed Mar 3, 2026 ΔOwn −44%

Valantine Hannah sold $978.3K of BBIO, trimming their stake 44%.

−$978.3K
14,584 sh @ $67
BBIO
BridgeBio Pharma, Inc.
Sell Valantine Hannah · Director · Open-market sale · filed Mar 3, 2026 ΔOwn −59%

Valantine Hannah sold $739.5K of BBIO, trimming their stake 59%.

−$739.5K
10,900 sh @ $68
BBIO
BridgeBio Pharma, Inc.
Sell Apuli Maricel · Chief Accounting Officer · Open-market sale · filed Feb 27, 2026 ΔOwn −1.6%

Apuli Maricel sold $132K of BBIO, trimming their stake 2%.

−$132K
2,000 sh @ $66
Advertisement
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Feb 23, 2026 ΔOwn −7.2%

Kumar Neil sold $1.34M of BBIO, trimming their stake 7%.

−$1.34M
18,923 sh @ $71
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Feb 23, 2026 ΔOwn −3.5%

Kumar Neil sold $614.7K of BBIO, trimming their stake 4%.

−$614.7K
8,528 sh @ $72
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Feb 23, 2026 ΔOwn −0.3%

Kumar Neil sold $43.8K of BBIO.

−$43.8K
602 sh @ $73
BBIO
BridgeBio Pharma, Inc.
Sell Apuli Maricel · Chief Accounting Officer · Open-market sale · filed Feb 18, 2026 ΔOwn −0.4%

Apuli Maricel sold $37.9K of BBIO.

−$37.9K
510 sh @ $74
BBIO
BridgeBio Pharma, Inc.
Sell Trimarchi Thomas · President and CFO · Open-market sale · filed Feb 18, 2026 ΔOwn −3.8%

Trimarchi Thomas sold $1M of BBIO, trimming their stake 4%.

−$1M
13,400 sh @ $75
BBIO
BridgeBio Pharma, Inc.
Sell Scott Randal W. · Director · Open-market sale · filed Feb 18, 2026 ΔOwn −8.8%

Scott Randal W. sold $141.2K of BBIO, trimming their stake 9%.

−$141.2K
1,900 sh @ $74
BBIO
BridgeBio Pharma, Inc.
Sell Scott Randal W. · Director · Open-market sale · filed Feb 18, 2026 ΔOwn −24%

Scott Randal W. sold $362.2K of BBIO, trimming their stake 24%.

−$362.2K
4,793 sh @ $76
BBIO
BridgeBio Pharma, Inc.
Sell Scott Randal W. · Director · Open-market sale · filed Feb 18, 2026 ΔOwn −22%

Scott Randal W. sold $251.1K of BBIO, trimming their stake 22%.

−$251.1K
3,307 sh @ $76
BBIO
BridgeBio Pharma, Inc.
Option exercise Kumar Neil · Director, Chief Executive Officer · Option exercise · filed Feb 18, 2026 ΔOwn +4.1%
+$0
11,554 sh
BBIO
BridgeBio Pharma, Inc.
Tax withholding Kumar Neil · Director, Chief Executive Officer · Tax withholding · filed Feb 18, 2026 ΔOwn −11%
−$2.33M
30,970 sh @ $75
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Feb 12, 2026 ΔOwn −1.1%

Kumar Neil sold $551.8K of BBIO, trimming their stake 1%.

−$551.8K
7,806 sh @ $71
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Feb 12, 2026 ΔOwn −0.5%

Kumar Neil sold $265.5K of BBIO, trimming their stake 1%.

−$265.5K
3,716 sh @ $71
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Feb 12, 2026 ΔOwn −0.7%

Kumar Neil sold $325.7K of BBIO, trimming their stake 1%.

−$325.7K
4,484 sh @ $73
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Feb 12, 2026 ΔOwn −0.6%

Kumar Neil sold $292.6K of BBIO, trimming their stake 1%.

−$292.6K
3,994 sh @ $73
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Feb 12, 2026 ΔOwn −0.2%

Kumar Neil sold $555.7K of BBIO.

−$555.7K
7,860 sh @ $71
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Feb 12, 2026 ΔOwn −0.1%

Kumar Neil sold $269.8K of BBIO.

−$269.8K
3,775 sh @ $71
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Feb 12, 2026 ΔOwn −0.1%

Kumar Neil sold $319.9K of BBIO.

−$319.9K
4,404 sh @ $73
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Feb 12, 2026 ΔOwn −0.1%

Kumar Neil sold $290.1K of BBIO.

−$290.1K
3,961 sh @ $73
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Feb 12, 2026 ΔOwn −2.0%

Kumar Neil sold $1.02M of BBIO, trimming their stake 2%.

−$1.02M
14,201 sh @ $72
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Feb 12, 2026 ΔOwn −0.8%

Kumar Neil sold $419.2K of BBIO, trimming their stake 1%.

−$419.2K
5,799 sh @ $72
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Feb 12, 2026 ΔOwn −0.3%

Kumar Neil sold $1.01M of BBIO.

−$1.01M
14,040 sh @ $72
Advertisement

About BBIO insider activity

This page tracks every recent Form 4 filed for BridgeBio Pharma, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is BBIO insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for BridgeBio Pharma, Inc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.